AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39019657
Drug: Booster vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccination (dose or brand unspecified)
Trial: 39019875
Drug: Desvenlafaxine 50
RxNorm normalized name: desvenlafaxine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 50 mg/day (D-50)
Trial: 39019875
Drug: Desvenlafaxine 100
RxNorm normalized name: desvenlafaxine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 100 mg/day (D-100)
Trial: 39020305
Drug: Cenegermin t.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenegermin t.i.d. (20 mcg/mL, 3 times daily)
Trial: 39020305
Drug: Cenegermin b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenegermin b.i.d. (20 mcg/mL, 2 times daily)
Trial: 39020305
Drug: Vehicle (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (once daily or t.i.d.)
Trial: 39020409
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (ET) for primary M3 occlusion
Trial: 39020446
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two additional doses of COVID-19 vaccines 3 months apart
Trial: 39020503
Drug: Guided Bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Bone Regeneration (GBR) treatment
Trial: 39020518
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy and neoadjuvant chemotherapy in combination with sindilizumab
Trial: 39020518
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy and neoadjuvant chemotherapy
Trial: 39022429
Drug: STOP group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STOP group (40,000 IU subcutaneous EPO combined with 20 mg/kg intravenous ferric carboxymaltose if Hb < 13 g/dL the day before surgery or at ICU admission, and RBC transfusion if Hb ≤ 8 g/dL)
Trial: 39022700
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitor use as intraarterial (IA) bolus + intravenous (IV) infusion
Trial: 39022796
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg days 1-21 plus dexamethasone 40 mg days 1, 8, 15, 22, administered in 28-day cycles for a total of 12 cycles
Trial: 39023063
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral anticoagulants (OAC)
Trial: 39023253
Drug: Abemaciclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib plus endocrine therapy for 2 years, followed by endocrine therapy for a total of at least 5 years.
Trial: 39023253
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy only for at least 5 years.
Trial: 39023253
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy only
Trial: 39023418
Drug: Prescriptions for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions for angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and statins
Trial: 39023538
Drug: Heparin anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin anticoagulation (HA)
Trial: 39023880
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg orally once daily for up to 52 weeks
Trial: 39023880
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once daily for up to 52 weeks
Trial: 39023900
Drug: 90 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 minutes per week of exercise therapy
Trial: 39023900
Drug: 150 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 minutes per week of exercise therapy
Trial: 39023900
Drug: 225 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 minutes per week of exercise therapy
Trial: 39023900
Drug: 300 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 minutes per week of exercise therapy
Trial: 39023900
Drug: 375 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 minutes per week of exercise therapy
Trial: 39023900
Drug: 450 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 minutes per week of exercise therapy
Trial: 39024037
Drug: Nivolumab (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (four cycles of 240 mg every 2 weeks, thereafter 480 mg every 4 weeks)
Trial: 39024364
Drug: Early norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early norepinephrine (NE) administration
Trial: 39024543
Drug: valoctocogene roxaparvovec
RxNorm normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valoctocogene roxaparvovec (6 × 10^13 vg/kg infusion)
Trial: 39024542
Drug: Once-weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly carfilzomib (56 mg/m2) plus lenalidomide and dexamethasone (KRd56)
Trial: 39024542
Drug: Twice-weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27)
Trial: 39024845
Drug: Active PSI-rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PSI-rTMS (10 Hz, 80% resting motor threshold, 5 daily sessions for 1 week, followed by weekly maintenance for 7 weeks)
Trial: 39025066
Drug: ABO1020 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABO1020 (15 μg per dose, 2 doses, administered 28 days apart)
Trial: 39025066
Drug: ABO1020 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABO1020 (1 or 2 doses)
Trial: 39025092
Drug: Initial oral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial oral antibiotics (coformulated amoxicillin 100 mg/kg per day and clavulanic acid 12.5 mg/kg per day for patients younger than 5 years; dicloxacillin 200 mg/kg per day for patients aged 5 years or older)
Trial: 39025092
Drug: Initial intravenous
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial intravenous antibiotics (ceftriaxone 100 mg/kg per day in one dose)
Trial: 39025264
Drug: nano-CBD cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano-CBD cream
Trial: 39025698
Drug: VAX-24 2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAX-24 2.2 mcg dose
Trial: 39025812
Drug: Evidence-based recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based recommendations for treatment following ACL rupture.
Trial: 39025971
Drug: Milvexian (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (200 mg; twice daily for 5 days) with aspirin (325 mg for 5 days)
Trial: 39025971
Drug: Milvexian (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (200 mg; twice daily for 5 days) with clopidogrel (Day 1: 300 mg; Days 2-5: 75 mg)
Trial: 39025971
Drug: Milvexian (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (200 mg; twice daily for 5 days) without aspirin or clopidogrel
Trial: 39025971
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with aspirin (325 mg for 5 days)
Trial: 39025971
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with clopidogrel (Day 1: 300 mg; Days 2-5: 75 mg)
Trial: 39025971
Drug: Placebo without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without aspirin or clopidogrel
Trial: 39026165
Drug: Granisetron transdermal
RxNorm normalized name: Granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron transdermal delivery system (GTDS) combined with Dexamethasone
Trial: 39026266
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (40 min daily over three consecutive days)
Trial: 39026266
Drug: Midazolam (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (active placebo, 40 min daily over three consecutive days)
Trial: 39026306
Drug: Aripiprazole oral
RxNorm normalized name: aripiprazole Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole oral solution (1 mg/mL, range: 2-20 mg, starting dose of 2 mg)
Trial: 39026552
Drug: Treatment requirements
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment requirements in GCA patients
Trial: 39026552
Drug: Treatment needs
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment needs in PMR patients
Trial: 39026620
Drug: Extracellular vesicles
RxNorm normalized name: Stem-cell derived extracellular vesicles
DrugBank: Stem-cell derived exosome vesicle products (DB15743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracellular vesicles (EVs) as a biological therapy for preventing postoperative AF
Trial: 39027143
Drug: Dostarlimab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab (500 mg intravenously every three weeks for four doses, then 1000 mg every six weeks)
Trial: 39027664
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (0.3 g inorganic nitrate twice/day)
Trial: 39028043
Drug: Mobilisation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilisation with ankle movement treatment 3 times per week for 4 weeks
Trial: 39028057
Drug: Cervical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical and thoracic mobilisation with conventional physical therapy
Trial: 39028360
Drug: Open-loop (sensor-augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-loop (sensor-augmented pump) insulin therapy
Trial: 39028412
Drug: SFX-01 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFX-01 300 mg BD for 28 days
Trial: 39028763
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg intravenous dexamethasone
Trial: 39028902
Drug: casirivimab/imdevimab 1200
RxNorm normalized name: casirivimab/imdevimab 1200 mg/10mL(300 mg/2.5mL x4)-1200 mg/10mL(300 mg/2.5mL x 4) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: casirivimab/imdevimab 1200 mg
Trial: 39028916
Drug: HER-Vaxx plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER-Vaxx plus chemotherapy
Trial: 39028918
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin therapy, specific dosage and duration not available
Trial: 39028918
Drug: Placebo control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control, specific dosage and duration not available
Trial: 39028923
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) trastuzumab/pertuzumab (HP)
Trial: 39028923
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) trastuzumab/pertuzumab (HP)
Trial: 39029295
Drug: Sotorasib 960
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib 960 mg once daily
Trial: 39029295
Drug: Sotorasib 240
RxNorm normalized name: sotorasib 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotorasib 240 mg once daily
Trial: 39029481
Drug: VLA15 (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLA15 (135 μg or 180 μg)
Trial: 39030060
Drug: HEV239 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV239 (recombinant HEV vaccine)
Trial: 39030060
Drug: Hepa-B (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepa-B (control vaccine)
Trial: 39030062
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (repeat viral-load testing and empirical onward treatment)
Trial: 39030919
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg daily for 10 weeks
Trial: 39031449
Drug: ARFID-PTP (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARFID-PTP (two 2-hour individual treatment sessions with an optional booster session at 4-week follow-up)
Trial: 39031824
Drug: Lenvatinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (20 mg daily) plus pembrolizumab (200 mg every 3 weeks; up to 35 cycles)
Trial: 39031963
Drug: Cemiplimab (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemiplimab (350 mg IV every 3 weeks for 5 cycles of 9 weeks/cycle, then 4 cycles of 12 weeks/cycle)
Trial: 39032787
Drug: Plant-based diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-based diet (PBD) with high potassium content delivered as a weekly food basket while continuing sodium zirconium cyclosilicate (SZC) for 3 weeks
Trial: 39032926
Drug: Intermittently dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittently dosed relacorilant in combination with nab-paclitaxel
Trial: 39032926
Drug: Nab-paclitaxel monotherapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel monotherapy
Trial: 39033046
Drug: Dual delayed-release
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual delayed-release esomeprazole (10 mg)
Trial: 39033201
Drug: Nasal antiseptic
RxNorm normalized name: 3M Skin and Nasal Antiseptic
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal antiseptic solution containing povidone-iodine (n=25)
Trial: 39033201
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (n=25)
Trial: 39033266
Drug: Food allergen-specific
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food allergen-specific substitutive diet (FASSD) as a 6-month dietary treatment option.
Trial: 39033367
Drug: Flushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flushing with 2 ml of clear follicular fluid from 2 to 3 dominant follicles after oocyte retrieval
Trial: 39033370
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg triptorelin (Decapeptyl)
Trial: 39033370
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of GnRH agonist
Trial: 39033369
Drug: DLBS3233 100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS3233 100-mg daily
Trial: 39033369
Drug: Metformin-XR 750
RxNorm normalized name: metFORMIN Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-XR 750 mg twice daily
Trial: 39033767
Drug: Lenalidomide 5
RxNorm normalized name: lenalidomide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 5 mg daily for 2 years
Trial: 39033770
Drug: Pirtobrutinib 200
RxNorm normalized name: PIRTOBRUTINIB 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirtobrutinib 200 mg orally once a day in 28-day cycles
Trial: 39033770
Drug: Pirtobrutinib 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirtobrutinib 150 mg orally once a day (1 patient)
Trial: 39034493
Drug: Lethally irradiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lethally irradiated lymphoma cells admixed with GM-K562 cells; maximum of 6 vaccines administered
Trial: 39034968
Drug: Avelumab plus
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab plus lorlatinib (100 mg once daily)
Trial: 39034968
Drug: Avelumab plus
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab plus crizotinib (250 mg twice daily)
Trial: 39035147
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel applied daily internally and externally to the genital area for approximately 6 months (short-term) and optionally up to 2 years (long-term)
Trial: 39035685
Drug: Combination acupoints
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination acupoints (Zhongwan, CV-12 and Zusanli, ST-36)
Trial: 39036981
Drug: VIR-2482 450
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2482 450 mg
Trial: 39036981
Drug: VIR-2482 1200
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2482 1200 mg
Trial: 39037543
Drug: HR070803 (liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR070803 (liposomal irinotecan) in combination with 5-fluorouracil and leucovorin, intravenous infusion from 60 to 80 mg/m²
Trial: 39038096
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (BMT) plus endovascular treatment (EVT)
Trial: 39038268
Drug: Carfilzomib, Lenalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) followed by high-dose melphalan (200 mg/m2)
Trial: 39038282
Drug: Digital health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital health coaching intervention, including asynchronous messages 1-2 times per week, unlimited access to the coach, and monthly videoconference or phone meetings over a 4-month period.
Trial: 39038477
Drug: Heterologous HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous HIV-1 vaccine regimen (Ad26.Mos4.HIV and clade C gp140)
Trial: 39038477
Drug: Heterologous HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous HIV-1 vaccine regimen
Trial: 39038479
Drug: Luspatercept (1·0-1·75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luspatercept (1·0-1·75 mg/kg body weight, subcutaneously, once every 3 weeks)
Trial: 39038479
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (450-1050 IU/kg body weight, subcutaneously, once a week; max total dose 80,000 IU)
Trial: 39038701
Drug: First-, second-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-, second-, or third-line systemic therapy for chronic GVHD
Trial: 39038815
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter through week 52.
Trial: 39038990
Drug: Topical menthol
RxNorm normalized name: menthol Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical menthol (1% menthol applied to hands and feet, two times a day)
Trial: 39039005
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia only (group G)
Trial: 39039387
Drug: Spesolimab IV
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab IV (450 mg, 900 mg, 1200 mg)
Trial: 39039387
Drug: Spesolimab SC
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab SC (300 mg, 600 mg)
Trial: 39039449
Drug: ABTL0812 (1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABTL0812 (1300 mg tid) combined with carboplatin (AUC 5) and paclitaxel (175 mg/m2)
Trial: 39039449
Drug: ABTL0812 (1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABTL0812 (1300 mg tid)
Trial: 39039488
Drug: TIME case
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIME case conferences structured based on cognitive behavioural therapy (CBT)
Trial: 39039509
Drug: Overnight peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight peripheral parenteral nutrition (PPN)
Trial: 39039609
Drug: Integrated management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated management strategies including health worker training, adaptation of HIV EHR for HTN/CVD care, and use of treatment partners
Trial: 39039666
Drug: Obinutuzumab-based immuno-chemotherapy
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab-based immuno-chemotherapy and maintenance
Trial: 39039833
Drug: TFP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFP block (20 ml 0.25% bupivacaine for each side)
Trial: 39039833
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block (20 ml 0.25% bupivacaine for each side)
Trial: 39040037
Drug: Integrative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative care (IC) model including ACS secondary prevention program and depression care (case screening, group counselling, individual problem-solving therapy)
Trial: 39040184
Drug: IVIG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (2 g/kg) alone
Trial: 39040184
Drug: IVIG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (2 g/kg) with high-dose aspirin (80-100 mg/kg/day) until fever subsided for 48 hours, followed by daily aspirin (3-5 mg/kg) for six weeks